|
|
Home  CMSC Online For MS Professionals MS News Room CMSC NewNews
|
CMSC NewNews |
|
|
CMSC NewNews
- March 19, 2008
A Reminder to CMSC Member Centers and Program Directors
The April 15 deadline is approaching for Foundation of CMSC scholarship applications in two areas: Applications for MS Workforce of the Future annual meeting scholarships and Summer Research Scholarships to fund medical students conducting research projects. Additionally, there are a limited number of annual meeting training scholarships available for Nurse Practitioners and Physician Assistants. Applications will be evaluated and awarded as they are received. Click here for more
- January 15, 2008
CMSC meets with a delegation of Multiple Sclerosis professionals from Rome, Italy
We had the pleasure of welcoming a delegation from the University of Rome "La Sapienza" and "Ospedale Sant' Andrea" in Rome, Italy to CMSC offices.click here for more
- July 30, 2007
Research identifies new genes linked with MS
CHICAGO (Reuters) - After decades of dead ends, scientists have identified two genes that may raise the risk of multiple sclerosis, lending insight into the causes of the debilitating disease.click here for more
- July 26, 2007
The Heuga Center for Multiple Sclerosis honors the Multiple Sclerosis Coalition at The Heuga Center's benefit
he Heuga Center for Multiple Sclerosis will honor the Multiple Sclerosis (MS) Coalition at The Heuga Center's 22nd Annual Autumn Benefit October 23, 2007 at the St. Regis Hotel in New York City. The MS Coalition is an affiliation of independent MS organizations dedicated to the enhancement of the quality of life for those affected by MS.click here for more
- May 8, 2007
A Sad Loss for the MS Community
Leonor Gold, a well-known and very prestigious Argentine neurologist, passed away this past weekend in Buenos Aires.click here for more
- April 18, 2007
Attention MS Nurses
When making your travel arrangements for attending the CMSC Annual Meeting please consider joining two of our premiere corporate sponsors, Biogen Idec and Elan Pharmaceuticals, on Sunday, June 3, for a breakfast program. Breakfast will be from 8:00-10:00 am at the Washington Hilton &Tower. More information on this exciting program will come during the conference. click here for more
- March 27, 2007
A Sad Loss for the MS Community
Our dear friend and nursing colleague, Linda Morgante, passed away on March 26, 2007 after a courageous struggle with cancer. click here for more
- February 23, 2007
MS Awareness Week Action Alert
In cross-collaboration, MS patient organizations and MS activists from around the world have come together during MS Awareness Week 2007 to call on Congress to increase federal funding for multiple sclerosis research. click here for more
- February 23, 2007
Patent Held by Genentech Is Revoked by Government
The Patent and Trademark Office has decided to revoke a fundamental patent held by Genentech, the biotechnology company, that was at the center of a recent Supreme Court decision.d estimates of the numbers of people affected by various neurological disorders including multiple sclerosis. click here for more
- February 22, 2007
New Study in Mice May Help Explain MS Remissions During Pregnancy
Researchers report that significant changes occur in the tissue of brain and spinal cord of pregnant mice that may help to explain why remission occurs in many women with multiple sclerosis during pregnancy. click here for more
- February 5, 2007
National MS Society Raises Concerns that Recent NIH Study Underestimates Number of People with MS in the U.S.
An article released in the January 30, 2007 issue of the journal Neurology reviews previously published estimates of the numbers of people affected by various neurological disorders including multiple sclerosis. click here for more
- December 14, 2006
Internationally Known MS Expert, Professor W. Ian McDonald, Dies
The whole MS community expresses its sadness over the loss of W. Ian McDonald, MB, ChB, PhD, a former advisor who made outstanding research contributions toward understanding multiple sclerosis. Professor McDonald was Emeritus Professor of Clinical Neurology at the Institute of Neurology at University College in London. click here for more
- November 17, 2006
Natalizumab alters T cell ratio in MS patients
Use of natalizumab in patients with multiple sclerosis (MS) alters the ratio of CD4+ to CD8+ T-cells in cerebrospinal fluid (CSF), researchers have shown. click here for more
- October 23, 2006
Schering gets US OK for Betaseron in early stage MS
FRANKFURT (Reuters) - German drugmaker Schering has received approval from U.S. regulators for the use of its Betaseron drug for early stage multiple sclerosis, it said on Monday. click here for more
- October 19, 2006
Methylthioadenosine effective in animal models of multiple sclerosis
Methylthioadenosine (MTA), an adenine nucleoside produced from S-adenosylmethionine, is effective in animal models of acute and chronic multiple sclerosis (MS), according to a report in the September issue of the Annals of Neurology. click here for more
- October 13, 2006
High-dose cyclophosphamide promising for severe refractory MS
In patients with moderate to severe refractory MS, high-dose cyclophosphamide may lead to disease stabilization and improved functionality and quality of life, according to early results of a study reported in the Archives of Neurology for October. click here for more
- October 6, 2006
Outcomes not necessarily worse with late-onset multiple sclerosis
Late-onset multiple sclerosis (MS) is not always associated with worse outcomes than earlier adult-onset MS, according to a report in the September issue of Neurology. click here for more
- October 4, 2006
Elan and Biogen say Tysabri approved in Canada
Ireland's Elan Corp and U.S. partner Biogen Idec said on Wednesday that Canadian regulators had approved their Tysabri drug as a treatment for relapsing-remitting multiple sclerosis. click here for more
- October 4, 2006
Early treatment of multiple sclerosis yields long-term benefits
Early and ongoing treatment with interferon beta-1a can provide lasting benefits to patients with relapsing-remitting multiple sclerosis (MS), according to a report in the second September issue of Neurology. click here for more
- September 28, 2006
OneNew data confirmed Antibodies to COPAXONE® Do Not Impact its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
New data presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that antibodies to COPAXONE® (glatiramer acetate injection) developed in all patients with multiple sclerosis (MS) treated with COPAXONE®, but did not interfere with the efficacy of the drug. click here for more click here for more
- September 28, 2006
One-year Data from Phase III Trial Show that New Formulation of REBIF® Offers Substantial Improvement in Tolerability and Immunogenicity Profiles
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide. click here for more
- September 28, 2006
New data for FTY720 aiming to become the first orally effective multiple sclerosis treatment show sustained benefits over two years
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide. click here for more
- September 21, 2006
Serono's MS Treatment Gets Fast Track Status
Biotech company Serono said on Thursday its oral cladribine for the treatment of multiple sclerosis has been designated a fast track product by the U.S. Food and Drug Administration. click here for more
- September 14, 2006
FREEDOMS Trial (Fingolimod Research Evaluating Effects of Daily Oral Therapy in MS)
Phase II data showing clinical benefits of novel once-daily oral multiple sclerosis therapy FTY720 (fingolimod) published in New England Journal of Medicine. click here for more
- September 7, 2006
Medicare Reimbursement will be cut by 5.1% by 2007
If Congress does not act before the end of the year, Medicare reimbursement will be cut 5.1 percent in 2007. The time for Congress to prevent cuts to physician reimbursement is now! click here for more
- September 5, 2006
Cannabis-derived MS Treatment Filed in Europe
Sativex, the cannabis-derived product developed by GW Pharmaceuticals could be finally set for approval after a delay of around two years...click here for more
- March 8, 2006
SSDI Delays Query
It has become apparent in some states that delays in the time to decision for SSDI applications and appeals, in general, and for persons with MS in particular, have become significantly longer than previously....click here for more
- March 7, 2006
Medicare Suspends Cap On Rehabilitation Services For Beneficiaries With MS
On January 1, 2006, Medicare beneficiaries became subject to a $1,740 cap on outpatient PT and speech language pathology services and a separate $1,740 per beneficiary limit on occupational therapy....click here for more
- January 29, 2006
March is MS Foundation's MS Education and Awareness Month
March has been designated National MS Education & Awareness Month by the Multiple Sclerosis Foundation (MSF). The primary goals of this month are to increase awareness about MS and to educate and empower those affected by the disease...click here for more
|
|
|
